Personalized Arthritis Medication for Rheumatoid Arthritis
(SUPRA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
Is the personalized arthritis medication generally safe for humans?
The safety of JAK inhibitors, a type of medication used for rheumatoid arthritis, has been studied, showing that they can cause side effects like serious infections and reactivation of herpes zoster (shingles). However, these side effects are similar to those seen with other advanced arthritis treatments.12345
How is the drug tofacitinib unique for treating rheumatoid arthritis?
What data supports the effectiveness of the drugs used in the Personalized Arthritis Medication for Rheumatoid Arthritis trial?
Research shows that Janus kinase inhibitors (JAK inhibitors) like tofacitinib, baricitinib, upadacitinib, and filgotinib can be effective for patients with rheumatoid arthritis who haven't responded well to other treatments. These drugs have been shown to help reduce symptoms and improve patient-reported outcomes in clinical trials.12378
Who Is on the Research Team?
Marie Hudson, MD MPH
Principal Investigator
Sir Mortimer B. Davis - Jewish General Hospital
Are You a Good Fit for This Trial?
The SUPRA trial is for adults over 18 with Rheumatoid Arthritis who haven't improved after standard treatments. It's split into two parts: one for those needing a second-line treatment, and another for those where TNF inhibitors didn't work. Participants must be able to consent and fill out forms in English or French.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive various treatments including TNFi, JAKi, and Anti-IL6 receptor monoclonal antibodies
Follow-up
Participants are monitored for safety and effectiveness after treatment
Feasibility Assessment
Assessment of feasibility outcomes such as patient adherence and recruitment rates
What Are the Treatments Tested in This Trial?
Interventions
- Anti-IL6
- JAKi
- TNFi
Anti-IL6 is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Marie Hudson, MD
Lead Sponsor
Lady Davis Institute
Collaborator
Montreal General Hospital
Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborator